

# MAKING STRIDES TOWARDS NEW TREATMENTS

## ONE ENDPOINT AT A TIME

### IMPROVE ENDPOINT RELIABILITY

SmartSignals eCOA includes electronic versions of common AD study scales such as ADAS-Cog and MMSE, as well as built-in internal logic, preset workflows, edit checks, and audio/video recording capabilities. These features optimize scoring accuracy and consistency, and when used in conjunction with our Blinded Data Analytics, published data show a significant reduction in errors as well as increased ClinRO and endpoint data reliability.

### MAXIMIZE RATER ACCURACY

AD studies rely heavily on clinician-rated outcome assessments so we focus on qualifying, training, and certifying raters for these studies. Our experts identify errors and recalibrate raters as needed throughout the course of a study to ensure data validity.

### MONITOR AND MANAGE RISKS TO DATA QUALITY

Reliable and accurate data is the cornerstone to any successful clinical trial but especially vital in Alzheimer's studies which suffer extremely high failure rates. Signant provides numerous in-study data quality monitoring and data analysis solutions to identify, correct, and prevent common issues such as errors, bias, or fraud.

### COMMON LIBRARY MEASURES USED IN ALZHEIMER'S CLINICAL TRIALS

- ADAS-COG
- MMSE
- CDR
- RBANS
- ADCS-ADL

**ASK US FOR A COMPLETE LIST.**

Alzheimer's Disease (AD) studies are notoriously complex, long, and suffer high failure rates, but research is critical in the continued effort to identify disease-modifying treatments. Signant Health can apply decades of direct experience, deep expertise, and innovative clinical trial technologies within our SmartSignals™ platform to help researchers detect signal while increasing the quality and reliability of data generated.

### ENGAGE AND RETAIN PATIENTS IN LONG-TERM FOLLOW UP STUDIES


Participating in clinical trials can be difficult for people living with Alzheimer's. Signant's eConsent solutions simplify home-based consent, while our Patient Concierge engages and reminds participants and their caregivers/study partners during long-term follow up studies, improving retention in these critical phases.

### SENSITIVE MEASURES INCREASE SIGNAL DETECTION

Help your study team collect accurate data using highly sensitive sensors and assessments to improve signal detection. ActiGraph integration with our eCOA solution automates collection of activity and sleep data, and our proprietary computerized Cognitive Assessments help researchers detect subtle cognitive function changes over time.

Signant's end-to-end suite of evidence generation solutions and accompanying Alzheimer's clinical science and medicine expertise reduce burdens for participants and study teams while generating more accurate, reliable data to improve the probability of study success.

# SIGNANT'S ALZHEIMER'S DISEASE CLINICAL TRIAL SOLUTIONS EXPERIENCE



## SMARTSIGNALS SOLUTIONS

The SmartSignals solutions can be used individually or integrated together for a seamless, end-to-end digital experience.

### eCOA



### Blinded Data Analytics



### Activity Monitoring



### eConsent



## DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



**MEET THE EXPERTS**